EBMT 2024 | Optimizing bridging therapy for CAR-T in children and young adults with R/R ALL
Christina Peters
• 15 Apr 2024
Christina Peters, MD, St. Anna Children’s Hospital, Vienna, Austria, discusses the optimization of bridging therapy prior to CAR T-cells for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) in children and young adults. She suggests that complete leukemic cell eradication prior to CAR-T therapy may not always be necessary, advocating for milder chemotherapy options. Bridging therapy decisions should be tailored based on age and disease stage. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
